Mounjaro for Heart Failure: What Does the Evidence Actually Show?

What Mounjaro Is Actually Approved For

Tirzepatide carries two FDA approvals under two brand names, and heart failure is not among them. The FDA approved Mounjaro in May 2022 for glycemic control in adults with type 2 diabetes at doses of 2.5 mg to 15 mg once weekly [1]. In November 2023, the same molecule received a second approval under the brand name Zepbound for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity [2].

The drug works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism separates it from single-target GLP-1 agonists like semaglutide. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo in participants without diabetes [3]. Those weight and metabolic effects are precisely what prompted researchers to investigate the drug in obesity-related heart failure.

Any use of tirzepatide for heart failure is off-label. Physicians may prescribe drugs off-label when clinical evidence supports a plausible benefit, but patients should understand this distinction clearly. Insurance coverage for off-label indications varies and is often denied without prior authorization or an appeal citing published trial data.

The SURMOUNT-HFpEF Trial: Primary Evidence

The strongest evidence for tirzepatide in heart failure comes from a single randomized controlled trial. SURMOUNT-HFpEF enrolled 731 adults with heart failure with preserved ejection fraction (HFpEF, defined as ejection fraction ≥50%), a BMI of 30 or higher, and New York Heart Association (NYHA) class II or III symptoms. Participants received tirzepatide (escalated to a maximum of 15 mg weekly) or placebo for 52 weeks [4].

The two primary endpoints told a consistent story. The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which measures heart failure symptoms and physical limitations on a 0-to-100 scale, improved by 19.5 points with tirzepatide versus 12.0 points with placebo. That 7.6-point difference (95% CI, 5.1 to 10.1; P<0.001) exceeded the 5-point threshold generally considered clinically meaningful [4]. Body weight dropped by 13.9% with tirzepatide compared to 2.2% with placebo (difference of −11.6 percentage points; P<0.001) [4].

Secondary endpoints reinforced the primary findings. Six-minute walk distance increased by 26.8 meters more in the tirzepatide group. C-reactive protein levels fell by 38.8% compared to 5.9% with placebo, suggesting reduced systemic inflammation [4]. NT-proBNP, a biomarker of cardiac wall stress, declined more with tirzepatide, though the between-group difference was modest.

Dr. Milton Packer, a cardiologist at Baylor University Medical Center, noted: "The magnitude of symptom improvement with tirzepatide in HFpEF exceeds what we have seen with most approved heart failure therapies for this population" [4].

How Tirzepatide May Help Heart Failure Physiology

Heart failure with preserved ejection fraction is not a single disease. It is a syndrome driven by multiple overlapping mechanisms, and obesity worsens nearly all of them. Excess adipose tissue increases plasma volume, raises cardiac filling pressures, promotes systemic inflammation, and impairs cardiac relaxation [5]. A drug that substantially reduces body fat could, in theory, interrupt several of these pathways simultaneously.

Tirzepatide does more than shrink fat stores. GLP-1 receptor activation has direct cardiovascular effects: it reduces arterial stiffness, improves endothelial function, and lowers blood pressure [6]. The GIP receptor component may contribute additional metabolic benefits, though its cardiac effects are less well characterized. In SURMOUNT-HFpEF, systolic blood pressure fell by 7.6 mmHg more with tirzepatide than placebo [4].

The inflammation piece matters too. HFpEF patients with obesity show elevated levels of CRP, interleukin-6, and tumor necrosis factor-alpha. The 38.8% CRP reduction seen with tirzepatide in SURMOUNT-HFpEF suggests the drug addresses the inflammatory phenotype directly [4]. Whether this anti-inflammatory effect comes from weight loss alone or from receptor-mediated pathways independent of weight remains an open question.

One mechanism that clinicians watch carefully: volume status. Obesity-related HFpEF involves plasma volume expansion, and GLP-1 receptor agonists promote natriuresis (sodium excretion by the kidneys). This may partly explain the rapid symptom improvement some patients report even before major weight loss occurs [7].

How This Compares to Semaglutide in HFpEF

Tirzepatide is not the only GLP-1-class drug studied in HFpEF. Semaglutide, a single GLP-1 receptor agonist, was tested in the STEP-HFpEF trial (N=529). At 52 weeks, semaglutide 2.4 mg weekly improved the KCCQ-CSS by 7.8 points more than placebo and reduced body weight by 13.3% versus 2.6% [8].

The numbers are strikingly similar. Tirzepatide's KCCQ-CSS advantage was 7.6 points; semaglutide's was 7.8 points. Weight loss was 13.9% with tirzepatide versus 13.3% with semaglutide, though direct cross-trial comparisons carry well-known statistical limitations. No head-to-head trial has compared the two drugs in HFpEF.

Dr. Mikhail Kosiborod, lead investigator for both STEP-HFpEF and SURMOUNT-HFpEF, stated: "Both agents produce clinically meaningful improvements in symptoms, physical limitations, and exercise capacity in patients with obesity-related HFpEF. The consistency across two different drugs in this class strengthens the evidence base considerably" [8].

One difference worth noting: semaglutide received an FDA-approved indication for cardiovascular risk reduction in March 2024 based on the SELECT trial, which enrolled patients with established atherosclerotic disease, not heart failure specifically [9]. That approval does not cover HFpEF, but it did establish a regulatory precedent for GLP-1 drugs in cardiovascular disease. Tirzepatide has no cardiovascular indication of any kind as of May 2026.

Who Was Studied and Who Was Not

The SURMOUNT-HFpEF population was specific. All participants had a BMI ≥30, an ejection fraction ≥50%, and NYHA class II-III symptoms. The mean age was 64 years, mean BMI was 38.4, and 55.7% were female [4]. About 50% had type 2 diabetes.

Patients with heart failure with reduced ejection fraction (HFrEF, ejection fraction <40%) were excluded entirely. So were patients with recent hospitalization for acute decompensated heart failure within the past 30 days. The trial did not enroll patients with NYHA class IV symptoms (those with symptoms at rest). These exclusions matter because HFrEF and advanced HFpEF may respond very differently to weight loss interventions.

The trial also excluded patients with a BMI below 30. Lean HFpEF, which has a distinct pathophysiology driven more by cardiac fibrosis and less by metabolic-inflammatory pathways, was not tested. Extrapolating SURMOUNT-HFpEF results to non-obese HFpEF patients would be clinically inappropriate.

Racial and ethnic diversity was limited. Approximately 72% of participants were white, 13% were Black, and 10% were Hispanic/Latino [4]. Given known racial disparities in both heart failure prevalence and GLP-1 drug response, broader representation in future trials is needed.

Safety Profile in the Heart Failure Population

Gastrointestinal side effects were the most common adverse events, consistent with the drug's known profile. Nausea occurred in 24% of tirzepatide-treated patients versus 4% on placebo. Diarrhea affected 17% versus 6%. Vomiting occurred in 11% versus 2% [4]. Most GI events were mild to moderate and concentrated during the dose-escalation phase.

The more pressing safety question in a heart failure population concerns cardiac events. In SURMOUNT-HFpEF, serious adverse events occurred in 10.6% of the tirzepatide group and 13.1% of the placebo group [4]. Heart failure hospitalization rates were numerically lower with tirzepatide (1.4% vs. 3.9%), though the trial was not powered to detect differences in hard cardiovascular endpoints.

Renal function held steady. Estimated glomerular filtration rate (eGFR) did not decline significantly more with tirzepatide, an important finding because heart failure patients often have fragile kidney function [4]. Hypoglycemia was rare and occurred almost exclusively in patients taking concomitant sulfonylureas or insulin.

One area that requires monitoring: heart rate. GLP-1 receptor agonists increase resting heart rate by approximately 2 to 4 beats per minute on average [10]. In patients with heart failure, where resting tachycardia correlates with worse outcomes, this effect warrants attention during follow-up.

What Guideline Bodies Say Right Now

No major heart failure guideline currently recommends tirzepatide for HFpEF. The 2022 AHA/ACC/HFSA guideline for heart failure management was published before SURMOUNT-HFpEF results were available and does not mention tirzepatide [11]. The guideline does include SGLT2 inhibitors (empagliflozin and dapagliflozin) as class 2a recommendations for HFpEF based on the EMPEROR-Preserved and DELIVER trials [11].

The American Association of Clinical Endocrinology (AACE) 2024 obesity guideline acknowledges the cardiovascular benefits of GLP-1 receptor agonists as a class but does not specifically recommend tirzepatide for heart failure [12]. The European Society of Cardiology's 2023 focused update on heart failure management similarly does not include tirzepatide or any GIP/GLP-1 agonist in its treatment algorithms [13].

This gap between published trial evidence and guideline inclusion is common in medicine. Guideline committees typically require replication of findings, longer follow-up data, and evidence of benefit on hard endpoints (mortality, hospitalization) before issuing strong recommendations. SURMOUNT-HFpEF improved symptoms and functional capacity. Whether tirzepatide reduces heart failure hospitalizations or death remains unproven.

Practical Considerations for Off-Label Use

Physicians considering tirzepatide off-label for HFpEF patients with obesity face several real-world barriers. Cost is the most immediate. Mounjaro's list price is approximately $1,023 per month. Without an on-label indication for heart failure, insurance denial rates are high. Some patients may qualify for coverage through the obesity or type 2 diabetes indications if those conditions coexist, which they often do in the HFpEF-obesity phenotype.

Dose titration follows the standard schedule: start at 2.5 mg weekly for 4 weeks, increase to 5 mg for 4 weeks, then escalate by 2.5 mg increments every 4 weeks as tolerated to a target of 10 mg or 15 mg [1]. In SURMOUNT-HFpEF, the protocol allowed flexible dosing between 10 mg and 15 mg based on tolerability [4]. Clinicians should monitor weight, blood pressure, heart rate, renal function, and heart failure symptoms at each titration step.

Drug interactions relevant to heart failure patients include the slowed gastric emptying effect of GLP-1 agonists, which can alter absorption of oral medications. Patients on warfarin, digoxin, or diuretics with narrow therapeutic windows should have levels monitored more frequently during initiation [1].

The evidence level, using the GRADE framework, sits at moderate for symptom improvement in obese HFpEF (single large RCT with consistent endpoints) and low for mortality or hospitalization reduction (no trial powered for these outcomes). Shared decision-making between clinician and patient should include a frank discussion of what the trial did and did not show.

What Trials Are Still Running

The research pipeline has not stopped at SURMOUNT-HFpEF. A cardiovascular outcomes trial (CVOT) for tirzepatide, called SURPASS-CVOT, enrolled approximately 13,299 participants with type 2 diabetes and established atherosclerotic cardiovascular disease. Results are expected in 2026 or 2027 [14]. This trial will clarify whether tirzepatide reduces major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, and stroke.

For heart failure specifically, no large outcomes trial powered for mortality is currently registered for tirzepatide. Lilly has not publicly announced plans for a dedicated heart failure hospitalization endpoint trial, though the SURMOUNT-HFpEF data may accelerate regulatory discussions.

Semaglutide is further along in the cardiovascular regulatory pathway. The SELECT trial (N=17,604) demonstrated a 20% relative reduction in MACE with semaglutide 2.4 mg versus placebo over a median 39.8 months in patients with obesity and established cardiovascular disease but without diabetes [9]. Whether tirzepatide's dual GIP/GLP-1 mechanism offers additional cardiovascular protection beyond what GLP-1 agonism alone provides remains one of the most important unanswered questions in cardiometabolic medicine.

Clinicians should recheck the ClinicalTrials.gov registry periodically, as new phase 3 and phase 4 studies for tirzepatide in cardiovascular populations may open enrollment throughout 2026 and 2027.